Initiated by the EU project NANOMED2020, the European Nanomedicine Map provides thorough insights into the existing nanomedicine community by introducing on a single chart all the ecosystem‘s actors in Europe and beyond. This reference tool aims at increasing awareness, providing new networking opportunities, and at initiating fruitful partnerships.
A first step in the process of apprehending a discipline is to get a deeper view and understanding of the actors involved in this field.
With the European NanoMed Map, the nanomedicine community wins its own exploration tool displaying the top 1500 European actors, including stakeholders of nanomedicine as such, research centres, academia, SMEs and industries, healthcare providers, public and funding authorities, associations, clusters and infrastructures but also actors for which, nanomedicine will be an field of growing interest in the coming years.
“A map does not just chart, it unlocks and formulates meaning; it forms bridges between here and there, between disparate ideas that we did not know were previously connected.” ― Reif Larsen, The Selected Works of T.S. Spivet
The intrinsic value of such feature does not reside only in the many dots on the map, but in the detailed and easily accessible information about the actors’ research activities, products, areas of activities and specific transversal expertise. This NanoMed Map is therefore a real instrument for any nanomedicine enthusiast to trigger new collaborations and long-term partnerships between nanomedicine actors and beyond.
Such exhaustive mapping wouldn’t have been possible without extensive collaborations over the past nine months, surveys consolidations, online data and literature review. Compiling information publically available, the NanoMed Map led to the identification and classification of more than 1500 actors, including more than 500 industrial players and SMEs having a direct link or activity with the field, together with 1000 actors conducting research of excellence across Europe in Laboratories or Research Centres.
Leveraging its community of 120 members, the ETPN played a major role by providing the core data and by liaising with its associated networks to cover all European countries. This exercise also beneficiated from the fruitful relationships between the ETPN, the NANOMED2020 partners, the European Commission and national authorities to list all actors involved in FP7 projects or (trans)national activities.
NANOMED2020 called on the competences of the Berlin located start-up Hypermorgen to collaborate on the design, implementation and optimisation of the NanoMed Map.
This feature has been created to be interactive and dynamic, all nanomedicine actors are therefore invited to navigate through the map and eventually amend or add their entries.
This feedback is crucial to guarantee an up-to-date dynamic tool for the community, the national authorities and the general public.